세계의 혈소판 풍부 혈장 치료 시장 전망(-2030년) : 유형, 공급원, 용도, 최종 사용자 및 지역별 분석

According to Stratistics MRC, the Global Platelet-rich Plasma Therapy (PRP) Market is accounted for $710.94 million in 2023 and is expected to reach $1887.65 million by 2030 growing at a CAGR of 14.97% during the forecast period. A state-of-the-art medical technique called platelet-rich plasma therapy (PRP) uses the body's own natural healing abilities to encourage tissue regeneration. In order to concentrate the platelets-which are abundant in growth factors and proteins necessary for tissue repair-a small amount of the patient's blood is extracted during the course of the treatment.

According to the American Red Cross, PRP is greater than or equal to 5.5 × 1010 platelets per 50 mL. This translates to a two- to sevenfold increase in platelet concentration compared with that of whole blood. The normal human range of platelet concentration is 150 000 to 450 000 platelets per µL of whole venous blood.

Market Dynamics:

Driver:

Growing need for non-surgical and low-invasive therapies

Patients' increasing preference for procedures with less downtime and a lower risk of complications is driving the demand for non-surgical and minimally invasive treatments. PRP therapy is in line with this trend by providing a less invasive treatment for ailments like skin rejuvenation, tendon injuries, and chronic joint pain. Additionally, the concept of utilizing the body's natural healing processes instead of requiring extensive surgery appeals to patients.

Restraint:

Strict insurance protection

The limited insurance provider coverage of PRP therapy is a major impediment. PRP treatment is frequently paid for by the patient, which may be a deterrent for some people interested in this regenerative medicine. Moreover, a lack of broad insurance support could make it more difficult to use and less affordable, which would restrict its adoption, especially in areas where people rely more heavily on insurance.

Opportunity:

Increasing the use of clinical applications

An interesting prospect is the continuous investigation of novel clinical uses for PRP therapy. Determining PRP's regenerative potential in diseases that haven't been studied before can be the focus of future research. Additionally, PRP's potential therapeutic utility may be expanded by further investigating its effectiveness in neurology, cardiovascular medicine, and autoimmune disorders, among other diseases.

Threat:

Insufficient scientific consensus

The legitimacy of the therapy is at risk since there is no accepted definition or set of procedures for the preparation and administration of PRP. Moreover, healthcare providers may become skeptical of one another if treatment parameters and processing techniques vary and produce inconsistent results. To counter this threat, a unified scientific consensus must be established through research and consensus-building efforts.

COVID-19 Impact:

The market for platelet-rich plasma (PRP) therapy has been impacted by the COVID-19 pandemic in a number of ways. On the one hand, the adoption of PRP therapy has been impacted by the temporary slowdown in elective and non-urgent medical procedures brought on by disruptions in healthcare services, lockdowns, and resource reallocation towards pandemic response. However, the pandemic has highlighted the significance of regenerative medicine, placing a greater focus on patient-centered care and minimally invasive procedures. As healthcare systems stabilize, there should be a rise in demand for PRP therapy in the post-COVID recovery period, particularly in musculoskeletal conditions and aesthetic applications.

The Leukocyte-rich Platelet-rich Plasma (L-PRP) segment is expected to be the largest during the forecast period

The segment leukocyte-rich platelet-rich plasma (L-PRP) holds the largest share. A higher concentration of white blood cells, which are thought to be involved in tissue regeneration and the immune response, is a characteristic of L-PRP. This particular segment is preferred in some medical applications, especially in orthopedics, where the anti-inflammatory characteristics of leukocytes may help treat ailments like tendon injuries and osteoarthritis. Moreover, leukocytes are assumed to augment PRP's overall regenerative capacity, rendering L-PRP favored option in particular clinical situations. L-PRP has also been used in oral and maxillofacial surgery.

The Aesthetic Medicine segment is expected to have the highest CAGR during the forecast period

In the platelet-rich plasma (PRP) market, the aesthetic medicine segment is projected to have the highest CAGR. PRP therapy use in aesthetic medicine has increased dramatically, especially in cosmetic dermatology and facial rejuvenation. PRP is a sought-after treatment for skin rejuvenation, wrinkle reduction, and hair restoration because of its regenerative qualities, which encourage collagen production and tissue repair. Additionally, PRP treatments are minimally invasive, which is in line with the rising popularity of non-surgical aesthetic procedures. PRP is becoming more and more popular among people looking for long-lasting, natural cosmetic solutions as a result of growing knowledge of its efficacy in improving skin texture, treating hair loss, and improving overall facial aesthetics.

Region with largest share:

With the largest market share for platelet-rich plasma (PRP), North America has been a dominant region in the industry. Due to a number of factors, including a highly prevalent patient population that can benefit from regenerative therapies, substantial investment in research and development, and an advanced healthcare infrastructure, the United States in particular has contributed significantly to the growth of the PRP market. Furthermore, PRP treatments are now widely used in many medical specialties, including orthopedics, dermatology, and sports medicine. This is due in part to the region's strong focus on technological innovation in healthcare and its well-established regulatory framework.

Region with highest CAGR:

In terms of platelet-rich plasma (PRP) market growth, the Asia-Pacific region is projected to have the highest CAGR. As the world's population ages and becomes more aware of cutting-edge medical treatments, as well as the increasing prevalence of orthopedic and cosmetic concerns, the Asia-Pacific region-which includes countries like China, Japan, India, and South Korea-is seeing a sharp increase in demand for regenerative medicine. Plus, PRP therapy is becoming more and more popular in the areas of musculoskeletal disorders and sports medicine. Moreover, the area's growing importance in the global PRP market is a result of government initiatives supporting the development of healthcare infrastructure as well as a growing focus on medical tourism.

Key players in the market

Some of the key players in Platelet-rich Plasma Therapy (PRP) market include: Arthrex, Inc, Zimmer Biomet, EmCyte Corporation, Dr. PRP USA LLC, Juventix Regenerative Medical LLC, Johnson & Johnson Services, Inc., Terumo Corporation, Stryker, Apex Biologix and Celling Biosciences, Inc.

Key Developments:

In June 2023, Dr. PRP USA LLC is proud to announce it has received 510K approval from the Food & Drug Administration (FDA) for its PRP kits. Now that the 510K clearance is final, Dr. PRP can continue to expand its market providing PRP kits to medical providers.

In May 2023, Zimmer Biomet Holdings, Inc., a global medical technology leader, announced it has reached a definitive agreement to acquire OSSIS, a privately-held medical device company that specializes in personalized 3D printed implants, as well as complex hip replacements, including second-time hip replacements and replacements involving bone tumors and trauma.

In January 2023, Arthrex, a global leader in minimally invasive surgical technology, announced its ACL TightRope implant has received clearance from the U.S. Food and Drug Administration (FDA) for pediatric indications. The TightRope implant is used in the surgical treatment of orthopedic injuries and is the first and only fixation device for anterior cruciate ligament (ACL) injuries cleared for pediatric use.

Types Covered:

• Pure-Platelet-rich Plasma (P-PRP)
• Leukocyte-rich Platelet-rich Plasma (L-PRP)
• Pure-Platelet-rich Fibrin (P-PRF)
• Leukocyte-rich Platelet-rich Fibrin (L-PRF)
• Activated PRP
• Autologous Conditioned Plasma (ACP)
• Cellular PRP
• Other Types

Sources Covered:

• Autologous
• Allogenic
• Other Sources

Applications Covered:

• Orthopedics
• Dermatology
• Dental
• Sports Medicine
• Chronic Wounds
• Ophthalmology
• Aesthetic Medicine
• Cardiac Muscle Injury
• Other Applications

End Users Covered:

• Hospitals
• Clinics
• Research and Academic Institutes
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Application Analysis
• 3.7 End User Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

,

5 Global Platelet-rich Plasma Therapy (prp) Market, By Type

• 5.1 Introduction
• 5.2 Pure-Platelet-rich Plasma (P-PRP)
• 5.3 Leukocyte-rich Platelet-rich Plasma (L-PRP)
• 5.4 Pure-Platelet-rich Fibrin (P-PRF)
• 5.5 Leukocyte-rich Platelet-rich Fibrin (L-PRF)
• 5.6 Activated PRP
• 5.7 Autologous Conditioned Plasma (ACP)
• 5.8 Cellular PRP
• 5.9 Other Types

6 Global Platelet-rich Plasma Therapy (prp) Market, By Source

• 6.1 Introduction
• 6.2 Autologous
• 6.3 Allogenic
• 6.4 Other Sources

7 Global Platelet-rich Plasma Therapy (prp) Market, By Application

• 7.1 Introduction
• 7.2 Orthopedics
• 7.3 Dermatology
• 7.4 Dental
• 7.5 Sports Medicine
• 7.6 Chronic Wounds
• 7.7 Ophthalmology
• 7.8 Aesthetic Medicine
• 7.9 Cardiac Muscle Injury
• 7.10 Other Applications

8 Global Platelet-rich Plasma Therapy (prp) Market, By End User

• 8.1 Introduction
• 8.2 Hospitals
• 8.3 Clinics
• 8.4 Research and Academic Institutes
• 8.5 Other End Users

9 Global Platelet-rich Plasma Therapy (prp) Market, By Geography

• 9.1 Introduction
• 9.2 North America
  • 9.2.1 US
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 Italy
  • 9.3.4 France
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 New Zealand
  • 9.4.6 South Korea
  • 9.4.7 Rest of Asia Pacific
• 9.5 South America
  • 9.5.1 Argentina
  • 9.5.2 Brazil
  • 9.5.3 Chile
  • 9.5.4 Rest of South America
• 9.6 Middle East & Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 UAE
  • 9.6.3 Qatar
  • 9.6.4 South Africa
  • 9.6.5 Rest of Middle East & Africa

10 Key Developments

• 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 10.2 Acquisitions & Mergers
• 10.3 New Product Launch
• 10.4 Expansions
• 10.5 Other Key Strategies

11 Company Profiling

• 11.1 Arthrex, Inc
• 11.2 Zimmer Biomet
• 11.3 EmCyte Corporation
• 11.4 Dr. PRP USA LLC
• 11.5 Juventix Regenerative Medical LLC
• 11.6 Johnson & Johnson Services, Inc.
• 11.7 Terumo Corporation
• 11.8 Stryker
• 11.9 Apex Biologix
• 11.10 Celling Biosciences, Inc